From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
Anti-Mouse CD16.2 Antibody (9E9) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD16.2. Anti-Mouse CD16.2 Antibody (9E9) reacts with mouse CD16.2, also known as FcγRIV (Fc receptor, IgG, low affinity IV). Anti-Mouse CD16.2 Antibody (9E9) inhibits cellular CD16.2 expression and signaling and blocks FcγRIV. Anti-Mouse CD16.2 Antibody (9E9) can be used for the researches of cancer, inflammation and immunology, such as CT26 tumor and lung inflammation .
Acimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL) .
GMA-161 is a humanized IgG1 antibody that targets Fcγ receptor III (CD16). GMA-161 has the potential for the study of autoimmune disorders. The isotype control for GMA-161 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD16/CD32. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) is a chimeric antibody of the original 2.4G2 antibody (HY-P99125). Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) contains the LALA-PG mutation region. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) can block the combination of CD16 and FcγRs. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) can be used for the researches of immunology and cardiovascular disease.
Bexatamig (SAR-443579) is a trifunctional natural killer cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between natural killer cells and CD123-positive tumor cells. By activating natural killer cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes .
Anti-CD16a Antibody (3G8) is a pan-CD16-specific antibody. Anti-CD16a Antibody (3G8) binds to an epitope overlapping with CD16a’s Fc binding site, inhibiting CD16a-IgG Fc region interactions.Anti-CD16a Antibody (3G8) recognizes CD16a, CD16b, and CD16b-NA1 and NA2 allelotypes expressed by neutrophils .
Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal antibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology .
FCGR3B Human Pre-designed siRNA Set A contains three designed siRNAs for FCGR3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FCGR3A Human Pre-designed siRNA Set A contains three designed siRNAs for FCGR3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Zemlikafusp alfa (IPH6501) is a tetra-specific NK cell engager that targets CD20, CD16a, NKp46 and carries an IL-2 variant. Zemlikafusp alfa (IPH6501) is used in research for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma .
MEDI-3622 is a human monoclonal antibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer .
PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma .
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
Anti-Mouse CD16.2 Antibody (9E9) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD16.2. Anti-Mouse CD16.2 Antibody (9E9) reacts with mouse CD16.2, also known as FcγRIV (Fc receptor, IgG, low affinity IV). Anti-Mouse CD16.2 Antibody (9E9) inhibits cellular CD16.2 expression and signaling and blocks FcγRIV. Anti-Mouse CD16.2 Antibody (9E9) can be used for the researches of cancer, inflammation and immunology, such as CT26 tumor and lung inflammation .
Acimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL) .
GMA-161 is a humanized IgG1 antibody that targets Fcγ receptor III (CD16). GMA-161 has the potential for the study of autoimmune disorders. The isotype control for GMA-161 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD16/CD32. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) is a chimeric antibody of the original 2.4G2 antibody (HY-P99125). Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) contains the LALA-PG mutation region. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) can block the combination of CD16 and FcγRs. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) can be used for the researches of immunology and cardiovascular disease.
Bexatamig (SAR-443579) is a trifunctional natural killer cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between natural killer cells and CD123-positive tumor cells. By activating natural killer cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes .
Anti-CD16a Antibody (3G8) is a pan-CD16-specific antibody. Anti-CD16a Antibody (3G8) binds to an epitope overlapping with CD16a’s Fc binding site, inhibiting CD16a-IgG Fc region interactions.Anti-CD16a Antibody (3G8) recognizes CD16a, CD16b, and CD16b-NA1 and NA2 allelotypes expressed by neutrophils .
Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal antibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology .
Zemlikafusp alfa (IPH6501) is a tetra-specific NK cell engager that targets CD20, CD16a, NKp46 and carries an IL-2 variant. Zemlikafusp alfa (IPH6501) is used in research for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma .
MEDI-3622 is a human monoclonal antibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer .
PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma .
The FcγRIIIA/CD16a protein is a receptor for IgG and is optimally activated upon binding of aggregated antigen-IgG complexes, inducing antibody-dependent cellular cytotoxicity (ADCC). It mediates IgG effector function on natural killer cells, limiting viral load. Fc gamma RIII/CD16 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-His labeled tag.
Fc gamma RIII/CD16 Protein, a low-affinity receptor for IgG1, IgG2a, and IgG2b, is crucial for mediating neutrophil activation in response to IgG complexes. It functions redundantly with Fcgr4 and interacts with INPP5D/SHIP1, emphasizing its involvement in intracellular signaling pathways linked to immune responses. Fc gamma RIII/CD16's significance lies in facilitating cellular activation triggered by immunoglobulin binding. Fc gamma RIII/CD16 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-6*His labeled tag.
Fc gamma RIII/CD16 Protein, a low-affinity receptor for IgG1, IgG2a, and IgG2b, is crucial for mediating neutrophil activation in response to IgG complexes. It functions redundantly with Fcgr4 and interacts with INPP5D/SHIP1, emphasizing its involvement in intracellular signaling pathways linked to immune responses. Fc gamma RIII/CD16's significance lies in facilitating cellular activation triggered by immunoglobulin binding. Fc gamma RIII/CD16 Protein, Mouse (HEK293, C-His) is the recombinant mouse-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-6*His labeled tag.
Fc gamma RIII/CD16 Protein, a low-affinity receptor for IgG1, IgG2a, and IgG2b, is crucial for mediating neutrophil activation in response to IgG complexes. It functions redundantly with Fcgr4 and interacts with INPP5D/SHIP1, emphasizing its involvement in intracellular signaling pathways linked to immune responses. Fc gamma RIII/CD16's significance lies in facilitating cellular activation triggered by immunoglobulin binding. Fc gamma RIII/CD16 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (NA2, HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (Biotinylated, NA2, HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
The Fc gamma RIII/CD16 protein is a receptor for IgG and is optimally activated upon binding to aggregated antigen-IgG complexes, initiating antibody-dependent cellular cytotoxicity (ADCC) and preventing inappropriate effector cell activation. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIII/CD16 Protein, Rhesus Macaque (HEK293, His-Avi) is the recombinant Rhesus Macaque-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
The Fc gamma RIII/CD16 protein is a receptor for IgG and is optimally activated upon binding to aggregated antigen-IgG complexes, initiating antibody-dependent cellular cytotoxicity (ADCC) and preventing inappropriate effector cell activation. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIII/CD16 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-His labeled tag.
The Fc gamma RIII/CD16 protein is a receptor for IgG and is optimally activated upon binding to aggregated antigen-IgG complexes, initiating antibody-dependent cellular cytotoxicity (ADCC) and preventing inappropriate effector cell activation. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIII/CD16 Protein, Rhesus Macaque (Biotinylated, HEK293, His-Avi) is the recombinant Rhesus Macaque-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
FCGR3A is a receptor for the Fc portion of immunoglobulin G that enhances antibody-dependent cell-mediated cytotoxicity and antibody-dependent viral infection. FCGR3A is also a potential immune oncogenic molecule and is related to the level of tumor immune infiltration. FCGR3A is often used as a biomarker with prognostic value in prostate cancer (PCa). Fc gamma RIIIA/CD16a Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-6*His labeled tag.
Fc gamma RIIIB/CD16b exhibits monoamine oxidase activity, showing specific preference for substrates such as 2-phenylethylamine and tryptamine. In addition to its enzymatic function, there are indications that Fc gamma RIIIB/CD16b may contribute to adipogenesis, suggesting a potential role in the complex regulation of adipose tissue development. Fc gamma RIIIB/CD16b Protein, Human (Biotinylated, NA1, HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIB/CD16b, expressed by HEK293 , with C-Avi, C-His labeled tag.
The FcγR4/CD16-2 protein is an IgG receptor with moderate affinity for IgG2a and IgG2b. It recognizes virus-specific IgG, triggers antibody-dependent cellular cytotoxicity, and provides protection against fatal influenza infection. FcgR4/CD16-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived FcgR4/CD16-2 protein, expressed by HEK293 , with C-His labeled tag.
The FcγR4/CD16-2 protein is an IgG receptor with moderate affinity for IgG2a and IgG2b. It recognizes virus-specific IgG, triggers antibody-dependent cellular cytotoxicity, and provides protection against fatal influenza infection. FcgR4/CD16-2 Protein, Mouse (HEK293, His-Avi) is the recombinant mouse-derived FcgR4/CD16-2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (HEK293, His) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-6*His labeled tag.
The FcγR4/CD16-2 protein is an IgG receptor with moderate affinity for IgG2a and IgG2b. It recognizes virus-specific IgG, triggers antibody-dependent cellular cytotoxicity, and provides protection against fatal influenza infection. FcgR4/CD16-2 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived FcgR4/CD16-2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (F176V, HEK293, SUMO-His) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-His, N-SUMO labeled tag and F176V mutation.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (F176V, HEK293, His-HSA) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-10*His, C-HSA labeled tag and F176V mutation.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (F176, S197P, HEK293, His) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-His labeled tag and F176, S197P, , , mutation. The total length of Fc gamma RIIIA/CD16a Protein, Human (F176, S197P, HEK293, His) is 192 a.a., with molecular weight of 35-45 kDa.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (CHO, His) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by CHO , with C-His labeled tag.
Fc γ RIIIA/CD16a is a receptor for the invariant Fc fragment of immunoglobulin γ (IgG). Fc γ RIIIA/CD16a regulates NK cell survival and proliferation and prevents NK cell progenitor cell apoptosis. Fc γ RIIIA/CD16a plays a role in mediating the anti-tumor activity of therapeutic antibodies by triggering TNFA-dependent ADCC, which promotes the entry of the virus into bone marrow cells during secondary infection and subsequent viral replication through antibody-dependent enhancement (ADE). Fc gamma RIIIA/CD16a Protein, Rat (HEK293, His) is the recombinant rat-derived Fc gamma RIIIA/CD16a, expressed by HEK293, with C-His labeled tag.
Fc γ RIIIA/CD16a is a receptor for the invariant Fc fragment of immunoglobulin γ (IgG). Fc γ RIIIA/CD16a regulates NK cell survival and proliferation and prevents NK cell progenitor cell apoptosis. Fc γ RIIIA/CD16a plays a role in mediating the anti-tumor activity of therapeutic antibodies by triggering TNFA-dependent ADCC, which promotes the entry of the virus into bone marrow cells during secondary infection and subsequent viral replication through antibody-dependent enhancement (ADE). Fc gamma RIIIA/CD16a Protein, Rat (HEK293, His, solution) is the recombinant rat-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-His labeled tag.
The FcγRIIIA/CD16a protein is a receptor for IgG and is optimally activated upon binding of aggregated antigen-IgG complexes, inducing antibody-dependent cellular cytotoxicity (ADCC). It mediates IgG effector function on natural killer cells, limiting viral load. Fc gamma RIIIA/CD16a Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (F176V, CHO, His) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by CHO , with C-His labeled tag and F176V mutation.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (F176V, HEK293, His) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-His labeled tag and F176V mutation.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (F176V, HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and F176V mutation.
rHuLow affinity immunoglobulin gamma Fc region receptor III-B/CD16b, His; Low affinity immunoglobulin gamma Fc region receptor III-B; Fc-gamma RIII-beta; FcR-10; IgG Fc receptor III-1; FCG3; FCGR3; CD16b and FCGR3B
Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (NA2, HEK293, His) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by HEK293 , with C-6*His labeled tag.
Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (Biotinylated, F176V, HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and F176V mutation.
Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (Biotinylated, NA2) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by E. coli , with tag free.
Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (NA2, CHO, His) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by CHO , with C-His labeled tag.
Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (NA2, HEK293, SUMO, His) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by HEK293, with N-SUMO and C-His labeled tag.
Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (NA2, HEK293, Twin Strep) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by HEK293, with C-Twin-Strep labeled tag.
CD16 antibody;
CD16a antibody;
CD16 antibody; Fc fragment of IgG antibody;
Fc fragment of IgG low affinity IIIa receptor (CD16) antibody; FcR10 antibody
WB, IHC-P, ICC/IF, IF-Tissue, mIHC
Human
CD16 Antibody (YA4660) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD16.
CD16a/b; CD32; CD32A/B; Fc fragment of IgG low affinity IIa/b receptor; Fc fragment of IgG low affinity IIIa/b receptor; Fc fragment of IgG low affinity IIIb receptor; Fc gamma receptor III A/B; FCG2A; FcGR; FCGR2A/BFCGR3; FCGR3A/B; Fc gamma RIIa/b
FC
Mouse
Rat Anti-Mouse CD16/32 Antibody (FITC)(YA3449) is a rat-derived and fluorescein isothiocyanate (FITC) IgG2b monoclonal antibody, targeting to CD16/32.
FCGR3B Human Pre-designed siRNA Set A contains three designed siRNAs for FCGR3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FCGR3A Human Pre-designed siRNA Set A contains three designed siRNAs for FCGR3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
